[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

DE69842165D1 - Herstellung attenuierter parainfluenza-virus impfstoffe aus klonierten nukleotidsequenzen - Google Patents

Herstellung attenuierter parainfluenza-virus impfstoffe aus klonierten nukleotidsequenzen

Info

Publication number
DE69842165D1
DE69842165D1 DE69842165T DE69842165T DE69842165D1 DE 69842165 D1 DE69842165 D1 DE 69842165D1 DE 69842165 T DE69842165 T DE 69842165T DE 69842165 T DE69842165 T DE 69842165T DE 69842165 D1 DE69842165 D1 DE 69842165D1
Authority
DE
Germany
Prior art keywords
piv
recombinant
attenuated
parain
preparation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69842165T
Other languages
English (en)
Inventor
Brian R Murphy
Peter L Collins
Anna P Durbin
Mario H Skiadopoulos
Tao Tao
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
US Department of Health and Human Services
Original Assignee
US Department of Health and Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by US Department of Health and Human Services filed Critical US Department of Health and Human Services
Application granted granted Critical
Publication of DE69842165D1 publication Critical patent/DE69842165D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/16Antivirals for RNA viruses for influenza or rhinoviruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62DNA sequences coding for fusion proteins
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011Details
    • C12N2760/18011Paramyxoviridae
    • C12N2760/18611Respirovirus, e.g. Bovine, human parainfluenza 1,3
    • C12N2760/18622New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011Details
    • C12N2760/18011Paramyxoviridae
    • C12N2760/18611Respirovirus, e.g. Bovine, human parainfluenza 1,3
    • C12N2760/18634Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Plant Pathology (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
DE69842165T 1997-05-23 1998-05-22 Herstellung attenuierter parainfluenza-virus impfstoffe aus klonierten nukleotidsequenzen Expired - Lifetime DE69842165D1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US4757597P 1997-05-23 1997-05-23
US5938597P 1997-09-19 1997-09-19
PCT/US1998/010551 WO1998053078A1 (en) 1997-05-23 1998-05-22 Production of attenuated parainfluenza virus vaccines from cloned nucleotide sequences

Publications (1)

Publication Number Publication Date
DE69842165D1 true DE69842165D1 (de) 2011-04-21

Family

ID=26725195

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69842165T Expired - Lifetime DE69842165D1 (de) 1997-05-23 1998-05-22 Herstellung attenuierter parainfluenza-virus impfstoffe aus klonierten nukleotidsequenzen

Country Status (10)

Country Link
EP (1) EP0994949B1 (de)
JP (2) JP4237268B2 (de)
KR (1) KR100702523B1 (de)
CN (1) CN1250725C (de)
AT (1) ATE501259T1 (de)
AU (1) AU7797798A (de)
BR (1) BR9809456B1 (de)
CA (1) CA2291216A1 (de)
DE (1) DE69842165D1 (de)
WO (1) WO1998053078A1 (de)

Families Citing this family (99)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7465574B2 (en) 1994-09-30 2008-12-16 Medimmune, Llc Recombinant RSV virus expression systems and vaccines
US7485440B2 (en) 1995-09-27 2009-02-03 The United States Of America As Represented By The Department Of Health And Human Services Production of attenuated respiratory syncytial virus vaccines involving modification of M2 ORF2
EP0912724B1 (de) 1996-07-15 2009-12-09 The Government of The United States of America, as represented by The Department of Health and Human Services Herstellung von attenuierten respiratorischen syncytialvirus-impfstoffen aus klonierten nukleotidsequenzen
US6699476B1 (en) 1996-07-15 2004-03-02 Peter L. Collins Production of recombinant respiratory syncytial viruses expressing immune modulatory molecules
US7201907B1 (en) 1997-05-23 2007-04-10 The United States Of America, Represented By The Secretary, Department Of Health And Human Services Attenuated human-bovine chimeric parainfluenza virus(PIV) vaccines
US7951383B2 (en) 1997-05-23 2011-05-31 The United States Of America As Represented By The Department Of Health And Human Services Attenuated parainfluenza virus (PIV) vaccines
US7314631B1 (en) 1997-05-23 2008-01-01 The United States Of America As Represented By The Department Of Health And Human Services Use of recombinant live-attenuated parainfluenza virus (PIV) as a vector to protect against disease caused by PIV and respiratory syncytial virus (RSV)
US7192593B2 (en) 1997-05-23 2007-03-20 The United States Of America, Represented By The Secretary, Department Of Health And Human Services Use of recombinant parainfluenza viruses (PIVs) as vectors to protect against infection and disease caused by PIV and other human pathogens
US6410023B1 (en) 1997-05-23 2002-06-25 United States Of America Recombinant parainfluenza virus vaccines attenuated by deletion or ablation of a non-essential gene
US20030082209A1 (en) 2000-07-05 2003-05-01 Skiadopoulos Mario H. Attenuated human-bovine chimeric parainfluenza virus (PIV) vaccines
US7632508B2 (en) 1997-05-23 2009-12-15 The United States Of America Attenuated human-bovine chimeric parainfluenza virus (PIV) vaccines
US7250171B1 (en) 1997-05-23 2007-07-31 United States Of America As Represented By The Dept. Of Health & Human Services Construction and use of recombinant parainfluenza viruses expressing a chimeric glycoprotein
US6830748B1 (en) 1997-09-26 2004-12-14 Medimmune Vaccines, Inc. Recombinant RSV virus expression systems and vaccines
WO1999064068A1 (en) 1998-06-12 1999-12-16 Mount Sinai School Of Medicine Of The City University Of New York Attenuated negative strand viruses with altered interferon antagonist activity for use as vaccines and pharmaceuticals
ES2301241T3 (es) 1998-06-12 2008-06-16 Mount Sinai School Of Medicine Of The City University Of New York Virus de influenza a atenuados, y composiciones inmunogenicas y formulaciones de vacunas que los contienen.
US6146642A (en) 1998-09-14 2000-11-14 Mount Sinai School Of Medicine, Of The City University Of New York Recombinant new castle disease virus RNA expression systems and vaccines
US6544785B1 (en) 1998-09-14 2003-04-08 Mount Sinai School Of Medicine Of New York University Helper-free rescue of recombinant negative strand RNA viruses
US8715940B2 (en) 1999-04-06 2014-05-06 Wisconsin Alumni Research Foundation Method of making recombinant influenza virus
KR100746979B1 (ko) 1999-04-13 2007-08-07 더 가버먼트 오브 더 유나이티드 스테이츠 오브 어메리카 애즈 리프리젠티드 바이 더 디파트먼트 오브 헬스 앤 휴먼 서비씨즈 클로닝된 뉴클레오티드 서열로부터의 약독화된 키메릭호흡기 신시티움 바이러스 백신의 제조
US7820182B2 (en) 1999-07-09 2010-10-26 The United States Of America As Represented By The Department Of Health And Human Services Production of attenuated, human-bovine chimeric respiratory syncytial viruses for use in immunogenic compositions
KR100940776B1 (ko) * 1999-07-09 2010-02-11 더 가버먼트 오브 더 유나이티드 스테이츠 오브 어메리카 애즈 리프리젠티드 바이 더 디파트먼트 오브 헬스 앤 휴먼 서비씨즈 약독화된 사람-소 키메라 파라인플루엔자바이러스(piv) 백신
CN100354425C (zh) 1999-07-09 2007-12-12 美国政府健康及人类服务部 减毒的人-牛嵌合呼吸道合胞病毒疫苗的生产
CA2362685A1 (en) * 1999-12-10 2001-06-14 Brian R. Murphy Use of recombinant parainfluenza viruses (pivs) as vectors to protect against infection and disease caused by piv and other human pathogens
US6764685B1 (en) * 2000-03-21 2004-07-20 Medimmune Vaccines, Inc. Recombinant parainfluenza virus expression systems and vaccines
WO2001077394A1 (en) 2000-04-10 2001-10-18 Mount Sinai School Of Medicine Of New York University Screening methods for identifying viral proteins with interferon antagonizing functions and potential antiviral agents
US6664066B2 (en) 2000-06-23 2003-12-16 Wyeth Holdings Corporation Modified Morbillivirus V proteins
WO2002002605A2 (en) * 2000-07-05 2002-01-10 The Government Of The United States Of America, As Represented By The Department Of Health And Human Services Attenuated human-bovine chimeric parainfluenza virus (piv) vaccines
DK1351981T3 (da) 2001-01-19 2012-11-26 Vironovative Bv Et virus, der forårsager luftvejssygdom hos modtagelige pattedyr
US8715922B2 (en) 2001-01-19 2014-05-06 ViroNovative Virus causing respiratory tract illness in susceptible mammals
EP1456398B1 (de) * 2001-11-21 2011-05-11 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Gewinnung von rekombinantem menschlichem parainfluenzavirus typ 1 (hpivi) aus cdna
AU2003219837B2 (en) 2002-02-21 2009-10-29 Erasmus University Medical Center Rotterdam Metapneumovirus strains and their use in vaccine formulations and as vector for expression of antigenic sequences
CA2482946C (en) 2002-04-26 2013-09-17 Medimmune Vaccines, Inc. Multi plasmid system for the production of influenza virus
US7465456B2 (en) 2002-04-26 2008-12-16 Medimmune, Llc Multi plasmid system for the production of influenza virus
WO2004027037A2 (en) 2002-09-18 2004-04-01 The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services RECOVERY OF RECOMBINANT HUMAN PARAINFLUENZA VIRUS TYPE 2 (HPIV2) FROM cDNA AND USE OF RECOMBINANT HPIV2 IN IMMUNOGENIC COMPOSITIONS AND AS VECTORS TO ELICIT IMMUNE RESPONSES AGAINST PIV AND OTHER HUMAN PATHOGENS
US7704491B2 (en) 2003-02-28 2010-04-27 The United States Of America As Represented By The Department Of Health And Human Services Recombinant human metapneumovirus and its use
JP2007525178A (ja) 2003-04-25 2007-09-06 メッドイミューン バクシーンズ,インコーポレイティド メタニューモウイルス株、そのワクチン製剤における用途、抗原性配列の発現のためのベクターとしての用途、並びにウイルス増殖方法
MX342639B (es) 2003-05-28 2016-10-07 Wisconsin Alumni Res Found Virus de la influenza recombinantes de alta titulacion para vacunas y terapia genica.
CN1871355B (zh) 2003-06-09 2011-12-14 惠氏 从cDNA中回收非节段性负链RNA病毒的改进方法
US7566458B2 (en) 2003-06-16 2009-07-28 Medimmune, Llc Influenza hemagglutinin and neuraminidase variants
ES2345492T3 (es) 2003-12-23 2010-09-24 Medimmune, Llc Sistema multiplasmido para la produccion del virus de la gripe.
AU2005248377B2 (en) 2004-05-25 2011-03-24 Medimmune, Llc Influenza hemagglutinin and neuraminidase variants
DK1773384T3 (en) 2004-06-01 2015-11-23 Us Agriculture GM swine influenza virus and uses thereof
CN101103103A (zh) 2004-11-19 2008-01-09 威斯康星旧生研究基金会 具有串联转录单位的重组流感病毒载体
US7572620B2 (en) 2005-01-11 2009-08-11 Wisconsin Alumni Research Foundation H3 equine influenza A virus
WO2006088481A2 (en) 2005-02-15 2006-08-24 Mount Sinai School Of Medicine Of New York University Genetically engineered equine influenza virus and uses thereof
WO2006098901A2 (en) 2005-03-08 2006-09-21 Medimmune Vaccines, Inc. Influenza hemagglutinin and neuraminidase variants
US7790434B2 (en) 2005-06-21 2010-09-07 Medimmune, Llc Methods and compositions for expressing negative-sense viral RNA in canine cells
WO2007002008A2 (en) 2005-06-21 2007-01-04 Medimmune Vaccines, Inc. Methods and compositions for expressing negative-sense viral rna in canine cells
PT2251034T (pt) 2005-12-02 2018-05-22 Icahn School Med Mount Sinai Vírus da doença de newcastle quiméricos que apresentam proteínas de superfície não nativas e suas utilizações
JP4905649B2 (ja) * 2006-03-08 2012-03-28 国立大学法人 長崎大学 魚用ワクチン、その製造方法、および魚類感染症の予防方法
EP2010557B1 (de) 2006-03-31 2014-02-26 Wisconsin Alumni Research Foundation Hochtitrige rekombinante influenzaviren für impfstoffe
PT2016194E (pt) 2006-04-19 2015-07-20 Medimmune Llc Métodos e composições para expressar arn viral de polaridade negativa em células caninas
US7601356B2 (en) 2006-07-21 2009-10-13 Medimmune, Llc Methods and compositions for increasing replication capacity of an influenza virus
KR101559184B1 (ko) 2006-08-09 2015-10-13 메디뮨 엘엘씨 인플루엔자 헤마글루티닌 및 뉴라미니다제 변이체
CA2690196A1 (en) 2007-06-18 2008-12-24 Medimmune, Llc Influenza b viruses having alterations in the hemaglutinin polypeptide
US9474798B2 (en) 2007-06-18 2016-10-25 Wisconsin Alumni Research Foundation Influenza M2 protein mutant viruses as live influenza attenuated vaccines
BRPI0915487A2 (pt) 2008-07-11 2017-06-27 Medimmune Inc hemaglutina de nfluenza e variantes de neuraminidase
EP2987856B1 (de) 2009-02-05 2018-07-25 Icahn School of Medicine at Mount Sinai Chimäre newcastle-krankheitsviren und verwendungen davon
RU2535970C2 (ru) 2009-02-12 2014-12-20 МЕДИММЬЮН, ЭлЭлСи Варианты гемагглютинина и нейраминидазы гриппа
AU2010234849B2 (en) 2009-03-30 2017-06-22 Mount Sinai School Of Medicine Influenza virus vaccines and uses thereof
WO2011014504A1 (en) 2009-07-27 2011-02-03 Mount Sinai School Of Medicine Of New York University Recombinant influenza virus vectors and uses thereof
US8828406B2 (en) 2009-07-30 2014-09-09 Icahn School Of Medicine At Mount Sinai Influenza viruses and uses thereof
EP2493912B1 (de) 2009-10-26 2020-07-29 Wisconsin Alumni Research Foundation Rekombinante influenzaviren mit hohem titer und erhöhter replikation in vero-zellen
US10130697B2 (en) 2010-03-23 2018-11-20 Wisconsin Alumni Research Foundation (Warf) Vaccines comprising mutant attenuated influenza viruses
EP3248615A1 (de) 2010-03-30 2017-11-29 Mount Sinai School of Medicine of New York University Influenzavirus-impfstoffe und verwendungen davon
US20130209406A1 (en) * 2010-06-06 2013-08-15 Benjamin R. tenOever Recombinant rna viruses and uses thereof
BR112014006694A2 (pt) 2011-09-20 2020-11-17 Mount Sinai School Of Medicine vacinas contra o vírus influenza e usos dessas
CA2895508A1 (en) 2012-12-18 2014-06-26 Icahn School Of Medicine At Mount Sinai Influenza virus vaccines and uses thereof
AU2014214763B2 (en) 2013-02-08 2020-02-27 The Research Foundation For The State University Of New York Attenuation of human respiratory syncytial virus by genome scale codon-pair deoptimization
CA2905272A1 (en) 2013-03-14 2014-10-02 Icahn School Of Medicine At Mount Sinai Newcastle disease viruses and uses thereof
WO2014159960A1 (en) 2013-03-14 2014-10-02 Icahn School Of Medicine At Mount Sinai Antibodies against influenza virus hemagglutinin and uses thereof
JP2016524915A (ja) 2013-07-15 2016-08-22 ウィスコンシン アルムニ リサーチ ファンデイション Mdck、ベロ細胞又は卵内で増強された複製を有する高力価の組換えインフルエンザウイルス
SG10201801562PA (en) 2014-02-27 2018-04-27 Viralytics Ltd Combination method for treatment of cancer
WO2015196150A2 (en) 2014-06-20 2015-12-23 Wisconsin Alumni Research Foundation (Warf) Mutations that confer genetic stability to additional genes in influenza viruses
EP3247389A4 (de) 2015-01-23 2019-10-30 Icahn School of Medicine at Mount Sinai Influenzavirusschutzimpfpläne
BR112017015789A2 (pt) 2015-02-26 2018-03-27 Boehringer Ingelheim Vetmedica Gmbh vacina de vírus da influenza suína bivalente
US10633422B2 (en) 2015-06-01 2020-04-28 Wisconsin Alumni Research Foundation (Warf) Influenza virus replication by inhibiting microRNA lec7C binding to influenza viral cRNA and mRNA
US9890363B2 (en) 2015-07-06 2018-02-13 Wisconsin Alumni Research Foundation (Warf) Influenza virus replication for vaccine development
AU2016308917A1 (en) 2015-08-20 2018-03-15 Cornell University Live-attenuated vaccine having mutations in viral polymerase for the treatment and prevention of canine influenza virus
WO2017031401A2 (en) 2015-08-20 2017-02-23 University Of Rochester Ns1 truncated virus for the development of canine influenza vaccines
US10548966B2 (en) 2015-08-20 2020-02-04 University Of Rochester Single-cycle virus for the development of canine influenza vaccines
US11197925B2 (en) 2016-02-19 2021-12-14 Wisconsin Alumni Research Foundation (Warf) Influenza B virus replication for vaccine development
EP3463439B1 (de) 2016-06-03 2022-08-03 University of Rochester Abgeschwächte lebendimpfstoffe gegen pferdeinfluenzavirus
JP7237344B2 (ja) 2016-06-15 2023-03-13 アイカーン スクール オブ メディシン アット マウント サイナイ インフルエンザウイルス血球凝集素タンパク質及びその使用
AU2017332789B2 (en) 2016-09-23 2021-05-27 Codagenix, Inc. Vaccine candidates for human respiratory syncytial virus (RSV) having attenuated phenotypes
JP2017038622A (ja) * 2016-11-21 2017-02-23 ウィスコンシン アルムニ リサーチ ファンデイション H3型ウマa型インフルエンザウイルス
CA3058652A1 (en) 2017-04-07 2018-10-11 Icahn School Of Medicine At Mount Sinai Anti-influenza b virus neuraminidase antibodies and uses thereof
JOP20190256A1 (ar) 2017-05-12 2019-10-28 Icahn School Med Mount Sinai فيروسات داء نيوكاسل واستخداماتها
JP7314059B2 (ja) 2017-05-29 2023-07-25 ザ ユナイテッド ステイツ オブ アメリカ アズ リプリゼンテッド バイ ザ セクレタリー、デパートメント オブ ヘルス アンド ヒューマン サービシーズ Rsv gを発現する組換えキメラウシ/ヒトパラインフルエンザウイルス3およびその使用法
CA3087239A1 (en) 2018-02-27 2019-09-06 University Of Rochester Multivalent live-attenuated influenza vaccine for prevention and control of equine influenza virus (eiv) in horses
US11166996B2 (en) 2018-12-12 2021-11-09 Flagship Pioneering Innovations V, Inc. Anellovirus compositions and methods of use
WO2020167432A2 (en) 2019-01-23 2020-08-20 Yoshihiro Kawaoka Mutations that confer genetic stability to additional genes in influenza viruses
WO2020163804A1 (en) 2019-02-08 2020-08-13 Wisconsin Alumni Research Foundation (Warf) Humanized cell line
BR112021016182A2 (pt) 2019-02-27 2021-11-03 Univ Kentucky Res Found Composição imunológica multivalente, e, método para induzir uma resposta imune contra uma pluralidade de vírus da influenza equina
US11390649B2 (en) 2019-05-01 2022-07-19 Wisconsin Alumni Research Foundation (Warf) Influenza virus replication for vaccine development
WO2021041624A2 (en) 2019-08-27 2021-03-04 Yoshihiro Kawaoka Recombinant influenza viruses with stabilized ha for replication in eggs
CN110628724B (zh) * 2019-09-25 2023-04-14 兰州生物制品研究所有限责任公司 一种三型副流感病毒野毒株及其应用
CN116348594A (zh) 2020-05-13 2023-06-27 美国卫生和人力服务部 携带一个或多个p基因突变的rsv疫苗
CN113462656B (zh) * 2021-03-24 2022-09-30 兰州生物制品研究所有限责任公司 一种人三型副流感病毒冷适应温度敏感株及其应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU7007491A (en) * 1990-02-02 1991-08-08 Schweiz. Serum- & Impfinstitut Bern Cdna corresponding to the genome of negative-strand rna viruses, and process for the production of infectious negative-strand rna viruses
DK0702085T4 (da) * 1994-07-18 2010-04-06 Conzelmann Karl Klaus Prof Dr Rekombinant infektiøs ikke-segmenteret negativ-strenget RNA-virus
JPH11513372A (ja) * 1995-09-22 1999-11-16 コノート ラボラトリーズ リミテッド パラインフルエンザウイルスの糖タンパクおよびワクチン
US5869036A (en) * 1995-12-08 1999-02-09 St. Louis University Live attenuated vaccines based on CP45 HPIV-3 strain and method to ensure attenuation in such vaccine

Also Published As

Publication number Publication date
BR9809456A (pt) 2000-06-13
CN1250725C (zh) 2006-04-12
EP0994949B1 (de) 2011-03-09
ATE501259T1 (de) 2011-03-15
KR20010012893A (ko) 2001-02-26
CN1306575A (zh) 2001-08-01
JP4384244B2 (ja) 2009-12-16
EP0994949A1 (de) 2000-04-26
CA2291216A1 (en) 1998-11-26
JP2002502241A (ja) 2002-01-22
JP4237268B2 (ja) 2009-03-11
BR9809456B1 (pt) 2011-06-28
KR100702523B1 (ko) 2007-04-04
JP2008307055A (ja) 2008-12-25
WO1998053078A1 (en) 1998-11-26
AU7797798A (en) 1998-12-11

Similar Documents

Publication Publication Date Title
DE69842165D1 (de) Herstellung attenuierter parainfluenza-virus impfstoffe aus klonierten nukleotidsequenzen
CA2230033A1 (en) Production of infectious respiratory syncytial virus from cloned nucleotide sequences
DE69737886D1 (de) Infektioese rna virus-klone, vakzine und davon abgeleitete diagnostische assays
ATE452210T1 (de) Rekombinante newcastle-disease-virus rna expressionssysteme und impfstoffe
DE60334310D1 (de) Dengue-vakzine mit einer gemeinsamen 30 nukleotid-deletion im 3'-utr der dengue-typen 1 und 2.
BR0016145A (pt) Clones infecciosos
WO2000003030A3 (en) Recombinant raccoonpox virus and uses thereof as a vaccine in mammalian and avian species
DK0702085T4 (da) Rekombinant infektiøs ikke-segmenteret negativ-strenget RNA-virus
CA2283464A1 (en) Functional dna clone for hepatitis c virus (hcv) and uses thereof
WO2000061737A3 (en) Production of attenuated negative stranded RNA virus vaccines
MXPA01013302A (es) Vacunas para el virus de la parainfluenza (piv) quimerico para humanos-bovinos atenuadas.
WO2002000169A3 (en) Production of vaccines using transgenic plants
BR0015740A (pt) Mutações de faixa de hospedeiro de vìrus de membrana e seus usos como substratos de vacinas
NO20006457L (no) Vaksine-indusert hepatitt B viral stamme og anvendelser derav
BR9806084A (pt) Vetor de poliovirus sabin tipo i, recombinante ou quimérico de replicação competente, seus métodos de produção e célula hospedeira
WO2000012677A3 (en) Generation of recombinant infectious bursal disease viruses by reverse genetics technology and the use of the recombinant viruses as attenuated vaccines
WO2002002605A3 (en) Attenuated human-bovine chimeric parainfluenza virus (piv) vaccines
HUP0002374A2 (hu) Egy diszfunkcionális 71 gén régiót tartalmazó rekombináns 1-es típusú ló herpeszvírus (EHV-1) és alkalmazása vakcinaként
WO2000075352A3 (en) Hcv/bvdv chimeric genomes and uses thereof
CA2562136A1 (en) Novel infectious bursal disease virus and vaccine containing said virus
WO2001011065A3 (en) Hepatitis a virus clones adapted for growth in agmk cells
Haller et al. Mx protein expression during infection of mice with pathogenic and apathogenic influenza A virus strains
TH63069A (th) โคลนก่อการติดเชื้อ